Trial Profile
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary)
- Indications Breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AbbVie
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 19 Jul 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.